Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Displaying 9102 questions Show Answers
To ask the Scottish Government what actions it is taking to ensure the sustainability of blood cancer diagnostic services.
To ask the Scottish Government how much of the £50 million announced in June 2022 to support a new approach to reduce A&E waiting times has been allocated to date, broken down by the amount allocated to each NHS board.
To ask the Scottish Government how many patients have been treated in each of the Early Cancer Diagnosis Centres that are currently operational to date.
To ask the Scottish Government how many nursing and midwifery training places that are available for the academic year 2022-23 are unfilled.
To ask the Scottish Government what steps it is taking to reduce the number of emergency blood cancer diagnoses following presentation at accident and emergency departments.
To ask the Scottish Government what discussions it has had with AstraZeneca, which is a manufacturer of tixagevimab–cilgavimab, also known as Evusheld, regarding how to ensure that patients in Scotland are able to access this preventative treatment for COVID-19.
To ask the Scottish Government when NHS Scotland will publish a winter resilience plan.
To ask the Scottish Government what work it is doing to ensure that pre-exposure prophylactics (PrEP) are available for immunocompromised patients, including people with myeloma, in relation to COVID-19.
To ask the Scottish Government what discussions it has had with the Department of Health and Social Care regarding the procurement of Evusheld.
To ask the Scottish Government, in light of reports that the Department of Health and Social Care has asked NICE to conduct an appraisal of remdesivir, tocilizumab, casirivimab and imdevimab, baricitinib, sotrovimab, molnupiravir, nirmatrelvir and ritonavir, and tixagevimab and cilgavimab for treating people with coronavirus disease 2019 (COVID-19) in the NHS in England, whether it will refer any of these currently available COVID-19 treatments to the Scottish Medicines Consortium.